Find out the winner of the 23rd edition of the Syva Award!

Find out the winner of the 23rd edition of the Syva Award!

Dr Roberto Sánchez Sánchez, from Madrid Complutense University, with his research work “Toxoplasmosis and neosporosis in domestic ruminants: normalization of animal models and evaluation of new drugs” won the 23rd Syva Award for best Doctoral Thesis in Animal Health of €15,000. Congratulations! 

 

The winning thesis was presented under the supervision of Drs Luis Miguel Ortega Mora, Ignacio Ferre Pérez and Michela Tatiana Re.

Dr Roberto Sánchez Sánchez is a vet who graduated from León University (2012) and was awarded a Doctorate “cum laude” from Madrid Complutense University, with a minor International Doctorate (2018).

He is currently a postdoctorate researcher with the UCM’s SALUVET group and has a contract with the Technological Platform for Research into Animal Health (PLATESA) for the Community of Madrid.

The Selection Board was chaired by Dr César B. Gutiérrez Martín (ULE), and comprised of Drs Ricardo de la Fuente López (UCM), Javier Lucientes Curdi (Unizar) and Rosario Bullido Gómez de las Heras (AEMPS). It also included Dr Maria Luisa de Arriba Martín, from Laboratorios Syva.

The research topic tackled Toxoplasma gondii and Neospora caninum, apicomplexan parasites responsible for reproductive failure in ovine-caprine livestock and bovine livestock, respectively. Moreover, T. gondii is a zoonotic agent with broad global distribution. Animal models are an essential tool to study the pathogeny of disease and to develop drugs and vaccines.

Currently, there are no effective drugs to treat these diseases in ruminants. The calcium dependent protein, kinase 1 (CDPK1), has recently been reported, against which a group of drugs known as “Bumped Kinase Inhibitors” (BKIs) have been developed with promising results.

The aim of the thesis was to normalize expectant ovine models with T. gondii and N. caninum infection and, using these, evaluate the safety and efficacy of BKIs. The thesis results comprise an essential proof of concept to reveal the usefulness of these compounds in monitoring both diseases in domestic ruminants.

You may also be interested in

13 May, 2024

The day after the first vaccinations in the Netherlands, Syva organised a round table in Utrecht focusing on the situation of bluetongue in this country and its BTV-3 vaccine.

Among those taking part in the day, many technical and practical questions that were answered by our experts, some of which reflected both the concern of being confronted once again with this BTV3 epidemic and a form of joy and relief at knowing that at the very moment many animals were being vaccinated.

Read more

10 May, 2024

The Belgian federal medicines agency, FAMHP, has now also authorised the use of the BTV3 vaccine developed by the Syva laboratories.

We are pleased to announce that, while Dutch veterinarians began mass vaccination on Monday 6 May, the Belgian veterinary health authorities on Wednesday 8 May authorised the use of Laboratories Syva's BTV3 vaccine under Article 110(2) of Regulation (EU) 2019/6.

Read more

26 April, 2024

Dutch authorities approved the use of the vaccine against bluetongue serotype 3 developed by Laboratorios Syva

After intensive work performed by our teams in our laboratories, an excellent coordination with the contract research organisations (CRO) which carried out the clinical trials necessary to test the vaccine's safety and efficacy, and an efficient communication with the authorities in the Netherlands, Syva Laboratories is pleased to announce that its vaccine against BTV 3 has been authorised for...

Read more